 <p><b>American Made Pharmaceuticals Act of 2022</b></p> <p>This bill requires the Centers for Medicare &amp; Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).</p> <p>The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.</p>